Merck & Co., Inc. (MRK)
收市後：
| 前收市價 | 106.93 |
| 開市 | 106.61 |
| 買盤 | 0.00 x 900 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 105.43 - 107.03 |
| 52 週波幅 | 81.64 - 115.49 |
| 成交量 | |
| 平均成交量 | 8,895,203 |
| 市值 | 267.897B |
| Beta 值 (5 年，每月) | 0.35 |
| 市盈率 (最近 12 個月) | 18.48 |
| 每股盈利 (最近 12 個月) | 5.71 |
| 業績公佈日 | 2023年4月27日 |
| 遠期股息及收益率 | 2.92 (2.73%) |
| 除息日 | 2023年3月14日 |
| 1 年預測目標價 | 119.54 |
- Insider Monkey
12 Best Diversified Dividend Stocks to Buy Now
In this article, we discuss 12 diversified dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best Diversified Dividend Stocks to Buy Now. Diversified companies can provide investors with diversification across different industries and sectors, which can help reduce […]
- Benzinga
Merck Releases Keytruda Data In Frontline Endometrial Cancer Patients
Merck & Co Inc (NYSE: MRK) announced results from the Phase 3 NRG‑GY018 trial of Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel), then continued as a single agent every six weeks for up to 14 cycles for the first-line treatment of stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient (pMMR) or mismatch repair deficient (dMMR). Keytruda, in combination with chemotherapy, reduced the risk of disease prog
- Insider Monkey
What Makes Merck & Co. (MRK) A Strong Investment?
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund returned 10.57% gross of fees, underperforming the Russell 1000 Value Index, which returned 12.42%. The underperformance of the fund relative to the benchmark in […]
